Pathos

Biotech & Life Sciences · Chicago, United States · Founded 2022

Pathos is a biotechnology company that operates at the intersection of artificial intelligence and oncology. The company's core mission is to accelerate the development of cancer drugs by leveraging a sophisticated platform that integrates vast amounts of oncology data, including genomic information. Pathos utilizes advanced AI and machine learning algorithms to analyze this complex data, aiming to re-engineer the drug development process. This data-driven approach allows the company to identify and validate novel therapeutic targets and biomarkers, ultimately leading to more effective and personalized cancer treatments. The company's business model is centered on collaborating with pharmaceutical and biotechnology partners to advance their oncology pipelines. By providing its AI-powered platform and insights, Pathos helps its clients to de-risk drug development, reduce timelines, and increase the probability of success for new cancer therapies. The company serves a clientele of researchers, drug developers, and clinicians in the oncology space. Keywords: biotechnology, artificial intelligence, oncology, drug development, genomics, machine learning, cancer treatment, personalized medicine, therapeutic targets, biomarkers

Valuation $1–2.5B

Headcount <100

Total funding $100–500M

Unlock exact values

Power Law Unicorn$1–10B valuation tier

Featured in

News Pathos AI acquires majority stake in DeuterOncology for AI-sourced cancer drug Jun 3, 2026

Investors

4 investors on Pathos's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 4 investors entered at this stage

NEA

Lightbank

Revolution

Builders VC

Global footprint

Where Pathos has talent and traffic

Workforce by country

1 countries with
team presence

🇺🇸 United States100%

1 country shown

Web traffic by country

7.4K monthly visits
across markets

🇺🇸 United States82.4%

🇮🇳 India16.2%

🇯🇵 Japan0%

Top 3 markets shown

Talent graph

The shape of Pathos's talent

Dealroom maps Pathos's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

9 standout operatorsDealroom-flagged across the org

4 AI specialistsincl. 2 core researchers

98 employees mappedperson by person

DimensionScore

AI Talentlive

Engineering

Product

Go-to-market

Leadership

Research

Book a demo to unlock Pathos's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$39k patent portfolio · 1 active families

Estimated portfolio value

$39k

<0.01% of valuation · 12513.2× smaller than top peer Genmab ($488M)

1 active patent families

Where Pathos innovates Animal bodyCancer preventionCancer researchCarcinosisCultured Cell Line

Where Pathos concentrates vs peers

Each axis is a top-10 topic across Pathos and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Pathos

An AI-synthesized read of the highest-engagement posts about Pathos on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Pathos on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles